Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Fleischhacker WW, et al. Among authors: walling dp. Lancet Psychiatry. 2021 Mar;8(3):191-201. doi: 10.1016/S2215-0366(20)30513-7. Lancet Psychiatry. 2021. PMID: 33610228 Clinical Trial.
Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Brown D, et al. Among authors: walling dp. Schizophr Bull. 2019 Mar 7;45(2):350-359. doi: 10.1093/schbul/sby049. Schizophr Bull. 2019. PMID: 29718385 Free PMC article. Clinical Trial.
Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.
Cohen EA, Hassman HH, Ereshefsky L, Walling DP, Grindell VM, Keefe RSE, Wyka K, Horan WP. Cohen EA, et al. Among authors: walling dp. Neuropsychopharmacology. 2021 Mar;46(4):844-850. doi: 10.1038/s41386-020-00911-5. Epub 2020 Nov 26. Neuropsychopharmacology. 2021. PMID: 33244149 Free PMC article. Clinical Trial.
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, Yagoda S, Bidollari I, Keane E, Cash E. Weiden PJ, et al. Among authors: walling dp. J Clin Psychiatry. 2020 May 19;81(3):19m13207. doi: 10.4088/JCP.19m13207. J Clin Psychiatry. 2020. PMID: 32433835 Free article. Clinical Trial.
58 results